Written by Athul Rajagopal, Graduate Student, University of Toronto & Bladder Cancer Canada Volunteer. 

What Is Lynch Syndrome? 

Lynch syndrome is a genetic condition that causes increased risk of several cancers, particularly at a younger age. Lynch syndrome is caused by mutations to genes that are involved in DNA repair, particularly mismatch repair. Normally, these genes are involved in repairing damaged DNA and ensuring that cells remain healthy. But when these mismatch repair genes fail, more mutations can accumulate, increasing the potential risk for uncontrolled cell growth and tumor formation. Due to this condition being inherited and causing a potential system breakdown, damaged DNA can accumulate much faster than the general population, resulting in younger populations becoming more vulnerable to developing cancer. 

Lynch Syndrome and Bladder Cancer Risk 

Despite being common in endometrial and colorectal cancers, lynch syndrome is also significantly associated with developing bladder cancer, with a 7.5 times higher risk than the general population. Furthermore, upper tract urothelial carcinoma is the third most common amongst the spectrum of lynch syndrome. Despite the association between cases of lynch syndrome and bladder cancer, there is a significant knowledge gap in understanding how the two are connected. Recent evidence suggests that the MSH2 mutation in lynch syndrome is most strongly associated to bladder cancer, with higher prevalence in MSH2 mutation families compared to the general population. However, the underlying biology remains poorly defined for bladder cancer, prompting the need for bladder-specific research in lynch syndrome. 

Genetic Screening and Early Detection 

Fortunately, through advances in medical biology, hereditary genetic screening of lynch syndrome has improved considerably. Modern approaches have enabled more accurate and early detection of genetic mutations in lynch syndrome, enabling proactive and preventative strategies for managing cancer. Enhanced screening of family members has also enabled detection of potential carriers of lynch syndrome, further improving prevention and management. In the clinical setting of bladder cancer, earlier detection of lynch syndrome allows for greater proactive management and surveillance using urinalysis and urine cytology, aiding early detection of tumors in younger patients. Newly developed urine tests have also shown promise in screening urinary tract cancers for patients diagnosed with lynch syndrome, allowing detection of early-stage tumors non-invasively. 

Treatment: Immunotherapy and Precision Medicine 

While surveillance is highly effective for early detection, urothelial cancers from lynch syndrome can still progress rapidly and are known to be aggressive. However, treatment of bladder tumors from lynch syndrome combines standard urological procedures with specialized immunotherapy, a form of treatment that supports the body’s immune system to attack cancer cells. Lynch syndrome cancers contain high mutation rates, which serve as important signals that the immune system can recognize. Immunotherapy takes advantage of this by empowering immune cells to attack and kill cancer cells. This is a great example of how research has enabled personalized medicine, where lynch syndrome patients benefit greatly from genetic-guided therapy. With further research, hopefully we can address the gaps to understand why bladder cancers arise frequently from lynch syndromes, which can further help management and prevention. 

Frequently Asked Questions 

What is Lynch syndrome? 

Lynch syndrome is an inherited genetic condition. It raises the risk of several cancers, including bladder cancer, often at a younger age. 

How much does Lynch syndrome raise bladder cancer risk? 

Lynch syndrome raises bladder cancer risk by about 7.5 times compared to the general population. 

Which Lynch syndrome gene mutation is most linked to bladder cancer? 

The MSH2 mutation shows the strongest link to bladder cancer among Lynch syndrome gene mutations. 

How is Lynch syndrome-related bladder cancer treated? 

Treatment combines standard urological procedures with immunotherapy. Immunotherapy helps the immune system find and attack cancer cells. 

References 

• Lynch syndrome: 10 things to know about this genetic condition | UT MD Anderson. https://www.mdanderson.org/cancerwise/qa-understanding-and-managing-lynch-syndrome.h00-158589789.html 
• Nassour, A.-J. et al. Relative Risk of Bladder and Kidney Cancer in Lynch Syndrome: Systematic Review and Meta-Analysis. Cancers (Basel) 15, (2023). 
• van der Post, R. S. et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J. Med. Genet. 47, 464-470 (2010). 
• Moussa, M. J. et al. Immune checkpoint inhibitors (ICIs) in advanced upper tract urothelial cancer (UTUC) with mismatch repair deficiency (dMMR) or microsatellite instability (MSI). JCO 43, 818-818 (2025).